RxDoctor Payments Data

Arnon Rubin, MD

Pulmonary Disease · Westmont, ILNPI 1245217413

Payments from drug & device makers

$10,419in general payments, 2019–2025

Across 93 payments — averaging $112.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$6K
  • Viiv Healthcare Company$2K
  • Mylan Specialty L.p.$747
  • Jazz Pharmaceuticals Inc.$663
  • Avadel CNS Pharmaceuticals, LLC$269
  • Boehringer Ingelheim$211
  • plus $824 from 19 others

What the payments were for

  • Consulting fees$2002%
  • Speaking & faculty fees$8,02277%
  • Travel & lodging$360%
  • Food & beverage$1,86718%
  • Education$2953%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,419 in reported general payments places this provider in the 75th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$148,199
Medicare patients
524
Services billed
1,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter115$91,769
XolairOmalizumab26$88,637
NucalaMepolizumab13$47,217
Breo ElliptaFluticasone/Vilanterol83$42,167
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$25,728
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$17,361
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$6,155
Albuterol Sulfate HfaAlbuterol Sulfate82$3,228
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,592
Montelukast Sodium40$558
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl13$431
Methylphenidate Hcl14$229
Zolpidem Tartrate19$119
Prednisone12$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta$6,105$187,308222 claims
AstraZenecaBreztri Aerosphere$71$25,72838 claims
Boehringer IngelheimStiolto Respimat$211$17,36124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Westmont

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →